Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate

Published: Jun 28, 2024 By Tristan Manalac

Nasdaq MarketSite, NY/iStock, hapabapa

Pictured: Nasdaq building in New York City/iStock, hapabapa

Alumis on Friday announced that it would proceed with its initial public offering, though with a smaller raise than it had recently hoped.

The San Francisco-based biotech will put more than 13,1 million shares of its common stock up for sale at $16 apiece. Concurrent with its initial public offering (IPO), Alumis will also sell 2.5 million additional shares in a private placement with AyurMaya Capital Management Fund. In total, the company expects to raise $260 million in gross proceeds, before taking away underwriting discounts and commissions.

Alumis can make more money from a 30-day over-allotment option, during which underwriters can purchase up to nearly 1,97 million additional shares of the biotech’s common stock at the IPO price. The…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks